Natus Medical plunges on missed Q2 sales

July 8, 2013 by Sony Salzman

Natus Medical's preliminary sales results for the 2nd quarter miss its own forecast, sending share prices down more than 12% today on Wall Street.

Natus Medical plunges on missed Q2 sales

Natus Medical (NSDQ:BABY) took a hit after the company announced missed 2nd-quarter sales, sending prices down more than 12% on Wall Street.

The San Carlos, Calif.-based company said it expects to post sales of $81 million to $82 million for the 3 months ended June 30, down 5.8%-8.9% from its prior guidance of $86 million to $90 million.

"Weakness in our International markets, particularly Europe, led to an unexpected decline in revenue late in the second quarter," CEO Jim Hawkins said in prepared remarks. "Domestic revenue was within our expectations."

Sign up to get our free newsletters delivered right to your inbox.

Natus said it will issue updated sales and earnings guidance for the 3rd quarter and 2013 during its Q2 earnings release, slated for August 1.

BABY shares were were down 12.8% to $12.47 as of 11:10 a.m. today.